Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation.
Samuel
D
D
Hospital P. Brousse, Villejuif, France.
Bismuth
H
H
Boillot
O
O
Ducerf
C
C
Baulieux
J
J
Gugenheim
J
J
Baldini
E
E
Launois
B
B
Messner
M
M
Wolf
P
P
Ellero
E
E
Domergue
J
J
Pageaux
J
J
Cherqui
D
D
Duvoux
C
C
Durand
F
F
Belghiti
J
J
Calmus
Y
Y
Massault
P P
PP
Neau-Cransac
M
M
Saric
J
J
LeTreut
Y
Y
Campan
P
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D001379:Azathioprine / Q000627:therapeutic use*; D002423:Cause of Death; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D001379:Azathioprine; D016559:Tacrolimus; D008775:Methylprednisolone